Info: Read More
  • 中药标准品生产商,产品定制服务
  • 胆固醇; 胆甾醇

    Cholesterol

    胆固醇; 胆甾醇
    产品编号 CFN90040
    CAS编号 57-88-5
    分子式 = 分子量 C27H46O = 386.67
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Steroids
    植物来源 The leaves of Olea europaea L.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    胆固醇; 胆甾醇 CFN90040 57-88-5 10mg QQ客服:1457312923
    胆固醇; 胆甾醇 CFN90040 57-88-5 20mg QQ客服:1457312923
    胆固醇; 胆甾醇 CFN90040 57-88-5 50mg QQ客服:1457312923
    胆固醇; 胆甾醇 CFN90040 57-88-5 100mg QQ客服:1457312923
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Mendel University in Brno (Czech Republic)
  • Seoul National University of Science and Technology (Korea)
  • The Ohio State University (USA)
  • Florida A&M University (USA)
  • S.N.D.T. Women's University (India)
  • Universita' Degli Studi Di Cagliari (Italy)
  • University of Amsterdam (Netherlands)
  • University of Hull (United Kingdom)
  • Leibniz Institute of Plant Biochemistry (Germany)
  • Chungnam National University (Korea)
  • Charles Sturt University (Denmark)
  • Mahidol University (Thailand)
  • Universitas islam negeri Jakarta (Indonesia)
  • Universidade Federal de Santa Catarina (Brazil)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Food Chem.2018, 262:78-85
  • HIV Med.2021, 22(8):690-704.
  • Cancers (Basel).2023, 15(1):37.
  • Food Res Int.2021, 148:110607.
  • J.of Traditional&Complementary Med.2022, 10.1016:j.jtcme.
  • Molecules.2022, 27(21):7643.
  • Primary and Industrial.2018, 52(11)
  • Food Funct.2021, 12(4):1469-1481.
  • Food Funct.2022, D1FO03838A.
  • University of Limpopo2016, 1-237
  • Histol Histopathol.2022, 18518.
  • Academic J of Second Military Medical University2019, 40(1)
  • Int J Mol Sci.2021, 22(12):6466.
  • Pharmaceutics.2020, 12(9):845.
  • Legume Science2021, 3(4): e101.
  • Toxicol In Vitro.2019, 59:161-178
  • J Hepatocell Carcinoma.2022, 9:327-341.
  • Chinese Medicine2019, 14(1)
  • J Agric Food Chem.2022, 70(51):16176-16187.
  • Phys Chem Chem Phys.2018, 20(23):15986-15994
  • Int J Mol Sci.2021, 22(9):5012.
  • Huazhong Agricultural University2022, pp34.
  • Molecules.2018, 23(9):E2121
  • ...
  • 生物活性
    Description: Cholesterol, a major eukaryotic lipid, can markedly modulate protein dynamics.The liposomal single-molecule approach highlighted the significance of the Cholesterol-induced basal force for interhelical interactions, which will aid discussions of complex protein-membrane systems.Cholesterol trafficking as an attractive therapeutic target for cancer treatment.
    Targets: VEGFR | mTOR
    In vivo:
    Am J Med. 2015 Apr;128(4):403-9.
    Cholesterol treatment and changes in guidelines in an academic medical practice.[Pubmed: 25460526]
    National guidelines are intended to influence physician Cholesterol treatment practices, yet few studies have documented the effect of new guidelines on actual prescribing behaviors and impacts on patient eligibility for treatment. We describe current Cholesterol treatment in an academic practice of Family and Internal Medicine physicians as well the effect of a change in Cholesterol treatment guidelines from 2001 Adult Treatment Panel III (ATPIII) to 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines.
    METHODS AND RESULTS:
    Medical records were extracted from primary care patients aged 40-75 years with at least one outpatient visit from January 1, 2012 to July 31, 2013; patients were included if they had records of Cholesterol testing, blood pressure measurement, sex, race, and smoking status. Patients were classified into ATPIII and ACC/AHA categories based on clinical variables (eg, diabetes, hypertension, atherosclerotic cardiovascular disease), Framingham Risk Score, and 10-year atherosclerotic cardiovascular disease risk. There were 4536 patients included in the analysis. Of these, 71% met ATPIII goals and 56% met ACC/AHA guidelines, a 15% decrease. Forty-three percent of high-risk patients met their low-density lipoprotein goals and 46% were on statins. Overall, 32% of patients would need to be started on a statin, 12% require an increased dose, and 6% could stop statins. Of patients considered low risk by ATPIII guidelines, 271 would be eligible for treatment by ACC/AHA guidelines, whereas 129 patients were shifted from intermediate risk to low risk with the change in guidelines.
    CONCLUSIONS:
    The ACC/AHA guidelines expand the number of patients recommended to receive statins, particularly among patients who were previously thought to be at moderate risk, and would increase the intensity of treatment for many patients at high risk. Significant numbers of patients at risk for cardiovascular events were not receiving guideline-based treatment. New Cholesterol guidelines may make treatment decisions easier.
    Biochem Biophys Res Commun. 2015 Feb 20;457(4):614-20.
    Cholesterol reduces the sensitivity to platinum-based chemotherapy via upregulating ABCG2 in lung adenocarcinoma.[Pubmed: 25603057]
    Inoperable lung adenocarcinoma is currently treated with platinum-based chemotherapy. However, the effectiveness of these chemotherapeutic agents is not the same for all patients.
    METHODS AND RESULTS:
    Patients either show quick chemoresistance (QCR) or delayed chemoresistance (DCR), which are defined by 87 and 242 days of progression-free survival (PFS) after initial platinum-based treatment, respectively. We found that QCR patients displayed an elevated level of serum cholesterol and that their tumors showed upregulated ABCG2 expression. We propose that chemoresistance may be attributed to cholesterol-induced ABCG2 expression and hypothesize that blocking ABCG2 may increase the efficacy of platinum-based chemotherapeutic agents. Using the MTT cell viability assay, we observed that cotreatment with ABCG2 blocker Nicardipine and platinum-based drugs Cisplatin, Oxaliplatin or Carboplatin significantly decreased cell viability of tumor cells.
    CONCLUSIONS:
    Importantly, our results also showed that incubating cells with cholesterol prior to chemotherapy treatment or cotreatment increased cell viability of tumor cells relative to the controls.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.5862 mL 12.9309 mL 25.8618 mL 51.7237 mL 64.6546 mL
    5 mM 0.5172 mL 2.5862 mL 5.1724 mL 10.3447 mL 12.9309 mL
    10 mM 0.2586 mL 1.2931 mL 2.5862 mL 5.1724 mL 6.4655 mL
    50 mM 0.0517 mL 0.2586 mL 0.5172 mL 1.0345 mL 1.2931 mL
    100 mM 0.0259 mL 0.1293 mL 0.2586 mL 0.5172 mL 0.6465 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    25R-牛膝甾酮; 25R-Inokosterone CFN93572 19682-38-3 C27H44O7 = 480.6 10mg QQ客服:1413575084
    土克甾酮; Turkesterone CFN90217 41451-87-0 C27H44O8 = 496.64 5mg QQ客服:2056216494
    蜕皮激素; Ecdysone CFN90487 3604-87-3 C27H44O6 = 464.63 5mg QQ客服:2159513211
    漏芦甾酮 B; Rhapontisterone B CFN90522 698975-64-3 C27H44O7 = 480.63 5mg QQ客服:2159513211
    20-羟基蜕皮甾酮; 20-Hydroxyecdysone CFN98873 5289-74-7 C27H44O7 = 480.6 20mg QQ客服:215959384
    水龙骨甾酮B; Polypodine B CFN89545 18069-14-2 C27H44O8 = 496.63 5mg QQ客服:215959384
    蜕皮甾酮-20,22-单丙酮化物; Ecdysterone 20,22-monoacetonide CFN98229 22798-96-5 C30H48O7 = 520.7 5mg QQ客服:215959384
    蜕皮甾酮2,3:20,22- 二缩丙酮; Ecdysterone 2,3:20,22-diacetonide CFN98230 22798-98-7 C33H52O7 = 560.8 5mg QQ客服:1413575084
    维生素D3; Vitamin D3 CFN90027 67-97-0 C27H44O = 384.64 20mg QQ客服:2056216494
    维生素D2; Ergocalciferol CFN90049 50-14-6 C28H44O = 396.65 20mg QQ客服:1457312923

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产